Which of the following substances cannot cross the blood-brain barrier?
Which anaesthetic is contraindicated in renal failure?
What is the concentration of adrenaline typically used with local anesthetics?
Anesthetic agent with vasoconstrictor is contraindicated in
What is the percentage of halothane that is metabolized in the human body?
Which of the following determines the speed of recovery from intravenous anesthesia?
Which sedative is most appropriate in a patient with hepatic impairment?
A patient undergoing a minor surgical procedure is given lignocaine injection. Assertion: Local anaesthetics act by blocking nerve conduction. Reason: Small fibers and non-myelinated fibers are blocked more easily than large myelinated fibers.
Which of the following statements about Nitrous Oxide (N2O) is true?
Which nerve is targeted in the nasociliary nerve block?
Explanation: ***Large protein molecule*** - The **blood-brain barrier (BBB)** is formed by tight junctions between endothelial cells, which restrict the passage of large molecules. - Large protein molecules **cannot easily diffuse** across these tight junctions and active transport mechanisms for such molecules are limited. *Glucose* - Glucose is essential for the brain's metabolism and actively crosses the BBB via **glucose transporters (GLUT1)** found on endothelial cells. - This active transport ensures a continuous supply of energy to the brain. *Oxygen* - Oxygen is a **small, lipid-soluble gas** that readily diffuses across the cell membranes of the BBB endothelial cells. - Its passage is crucial for **neuronal aerobic respiration**. *Lipophilic drug* - **Lipid-soluble (lipophilic) drugs** can easily dissolve in the lipid bilayer of the BBB endothelial cells and passively diffuse across the barrier. - This property is often exploited in drug design to target the central nervous system.
Explanation: ***Methoxyflurane*** - Methoxyflurane undergoes significant **metabolism** to produce inorganic **fluoride ions**, which are directly **nephrotoxic**. - This nephrotoxicity can cause **high-output renal failure** with reduced concentrating ability, making it contraindicated in patients with pre-existing renal impairment. *Isoflurane* - Isoflurane is minimally metabolized and produces very low levels of **fluoride ions**, making it generally **safe** for use in patients with renal failure. - Its elimination is primarily via the **lungs**, with very little hepatic metabolism or renal excretion of active compounds. *Desflurane* - Desflurane is also minimally metabolized, similar to isoflurane, and therefore produces negligible amounts of **fluoride ions**. - It is considered a **safe option** for patients with renal impairment due to its predominantly pulmonary elimination and lack of nephrotoxic metabolites. *Halothane* - While halothane can cause **hepatotoxicity**, it is generally **not directly nephrotoxic** in the way methoxyflurane is. - Its metabolism, though more extensive than isoflurane or desflurane, does not produce clinically significant levels of nephrotoxic fluoride ions to contraindicate its use in renal failure.
Explanation: ***1:200,000*** - This concentration of **adrenaline** (epinephrine) is commonly used with local anesthetics to prolong their duration of action and reduce systemic absorption. - It provides a good balance between efficacy in vasoconstriction and minimizing potential systemic side effects. *1:100,000* - While also used, this concentration provides a higher dose of **adrenaline**, which is often reserved for situations requiring more profound vasoconstriction or when a longer duration of action is critical. - It carries a slightly higher risk of systemic **epinephrine** effects compared to 1:200,000. *1:10,000* - This is a very high concentration of **adrenaline**, typically used for resuscitation in medical emergencies like **cardiac arrest** or **anaphylaxis**, not as an additive to local anesthetics for routine procedures due to significant risk of systemic toxicity. - Using such a high concentration would lead to severe vasoconstriction and a high likelihood of adverse cardiovascular events. *1:20,000* - This concentration is also very high for use with local anesthetics, although less concentrated than 1:10,000. It would still significantly increase the risk of systemic side effects. - It is not a standard concentration for routine local anesthetic admixture.
Explanation: ***Digital block*** - **Vasoconstrictors** in local anesthetics can cause severe **vasoconstriction** in tissues with limited collateral circulation, like digits. - This can lead to **ischemia**, **necrosis**, and even **gangrene** of the affected digit, making it a contraindication. *Spinal block* - **Vasoconstrictors** are sometimes added to local anesthetics for spinal blocks to prolong the duration of action and reduce systemic absorption. - While careful monitoring is needed, it is not an absolute contraindication and can be used cautiously. *Regional anesthesia* - In many forms of **regional anesthesia** (e.g., peripheral nerve blocks), vasoconstrictors like epinephrine are commonly added to prolong the block and reduce systemic toxicity. - This is a standard practice and generally safe outside of specific areas like digits. *Epidural block* - Similar to spinal blocks, **vasoconstrictors** are frequently used in **epidural anesthesia** to improve the quality, duration, and reduce systemic absorption of the local anesthetic. - While dose and patient factors must be considered, it is not a contraindication.
Explanation: **Correct: 25%** - Approximately **25%** of administered halothane is metabolized in the liver, which is a relatively high percentage compared to other volatile anesthetics. - This extensive metabolism can lead to the formation of reactive intermediates, contributing to its potential for **hepatotoxicity** (halothane hepatitis). *Incorrect: 50%* - **50%** metabolism is significantly higher than what is observed for halothane and would imply even greater risk of significant metabolic byproduct accumulation and toxicity. - Most volatile anesthetics are metabolized to a much lesser extent, with desflurane having the least metabolism (<0.02%). *Incorrect: 5%* - **5%** metabolism is too low for halothane; while some volatile anesthetics like isoflurane fall into this range (~0.2-2%), halothane is known for its considerably higher metabolic rate. - A 5% metabolism rate would result in less concern for and incidence of **halothane hepatitis**. *Incorrect: 2.50%* - **2.50%** metabolism is an underestimation of halothane's metabolic activity within the body. - Anesthetic agents such as **enflurane** have a metabolism rate closer to this value (~2-5%), whereas halothane is much higher.
Explanation: ***Redistribution of the drug from sites in the CNS*** - For many intravenous anesthetic agents, **redistribution** from highly perfused central nervous system (CNS) tissues to less perfused peripheral tissues is the primary mechanism for the termination of drug action and recovery from anesthesia. - This rapid decrease in the drug concentration at the site of action (brain) leads to the patient waking up, even before significant metabolism or excretion has occurred. *Liver metabolism of drug* - While liver metabolism is crucial for the **elimination** of many anesthetic drugs from the body, it is typically a slower process and contributes more to the overall drug clearance than to the immediate termination of the anesthetic effect. - Significant metabolism usually occurs after redistribution has already caused the patient to awaken. *Protein binding of drug* - **Protein binding** affects the free fraction of the drug available to act on receptors and to be metabolized or excreted. - However, it does not directly determine the speed of recovery, which is more dependent on the drug's movement between tissue compartments. *Plasma clearance of the drug* - **Plasma clearance** refers to the volume of plasma cleared of the drug per unit time, encompassing both metabolism and excretion. - While important for overall drug removal, it is generally a slower process compared to redistribution in determining the immediate end of intravenous anesthetic action.
Explanation: ***Lorazepam*** - **Lorazepam** is primarily metabolized by **glucuronidation**, a phase II metabolic pathway that is relatively preserved in most forms of hepatic impairment - This makes it a safer choice in patients with **liver disease** compared to other benzodiazepines that rely heavily on oxidative metabolism - Preferred sedative in cirrhosis and acute liver failure *Midazolam* - **Midazolam** is primarily metabolized by the **cytochrome P450 3A4 (CYP3A4)** enzyme system in the liver - Hepatic impairment can significantly reduce **CYP3A4 activity**, leading to prolonged half-life, increased sedative effects, and accumulation of the drug - Should be avoided or dose-reduced in hepatic impairment *Zolpidem* - **Zolpidem** is extensively metabolized by **hepatic cytochrome P450 enzymes**, particularly CYP3A4 and CYP2C9 - In patients with **hepatic impairment**, its clearance is significantly reduced, necessitating dose reduction to avoid excessive sedation and adverse effects - Maximum dose should be limited to 5 mg in hepatic dysfunction *Diazepam* - **Diazepam** undergoes extensive **hepatic oxidative metabolism** via CYP2C19 and CYP3A4 to active metabolites such as **desmethyldiazepam**, which also have long half-lives - In patients with **liver disease**, this metabolism is impaired, leading to prolonged drug action, increased sedation, and accumulation of the parent drug and active metabolites - Active metabolites can accumulate for days to weeks in hepatic impairment
Explanation: ***Both Assertion and Reason are true, and Reason is NOT the correct explanation for Assertion*** - The **Assertion** is true: Local anesthetics (like lignocaine) block nerve conduction by inhibiting **voltage-gated sodium channels**, preventing the depolarization necessary for action potential propagation - The **Reason** is also true: Small diameter and non-myelinated fibers (like C and Aδ pain fibers) are blocked more easily than large myelinated fibers (like Aα motor fibers), which explains the **differential blockade** pattern seen clinically - However, the **Reason does NOT explain WHY** local anesthetics block nerve conduction—it describes **WHICH** nerve fibers are blocked preferentially. The mechanism of blocking conduction is sodium channel inhibition, not fiber size selectivity - The differential sensitivity is a consequence of fiber characteristics (surface area-to-volume ratio, number of nodes of Ranvier), not the explanation for the blocking mechanism itself *Both Assertion and Reason are true, and Reason is the correct explanation for Assertion* - While both statements are individually true, the Reason does not explain the **mechanism** by which local anesthetics block nerve conduction - The Reason addresses fiber **selectivity**, which is a separate pharmacological property from the **mechanism of action** (sodium channel blockade) *Assertion is true, but Reason is false* - The Assertion is demonstrably true—local anesthetics block nerve conduction - The Reason is also true—this is well-established pharmacology: autonomic (small) > sensory (medium) > motor (large) fiber blockade sequence *Assertion is false, but Reason is true* - The Assertion is fundamentally correct and represents the primary pharmacological action of local anesthetics - Blocking nerve conduction is the therapeutic goal of local anesthetic administration
Explanation: **Least potent inhalational anesthetic** - Nitrous oxide has a **high Minimum Alveolar Concentration (MAC)** of approximately 104%, making it the least potent of the commonly used inhalational anesthetics. - Its high MAC means a very high concentration is required to achieve surgical anesthesia, which is why it is typically used as an adjunct to more potent agents. *Lighter than air* - The molecular weight of nitrous oxide (N2O) is 44, which is **heavier than air** (average molecular weight approximately 29 g/mol). - Its density is greater than air, meaning it would tend to sink rather than rise. *Effective muscle relaxant* - Nitrous oxide provides **minimal to no skeletal muscle relaxation** benefits. - If muscle relaxation is required, a neuromuscular blocking agent must be administered separately. *Does not cause diffusion hypoxia* - Nitrous oxide rapidly diffuses out of the blood into the alveoli during emergence, diluting the oxygen and carbon dioxide there. - This rapid diffusion can lead to **diffusion hypoxia** (also known as the "second gas effect"), necessitating the administration of 100% oxygen during recovery to prevent this complication.
Explanation: ***Nasociliary nerve*** - A nasociliary nerve block specifically targets the **nasociliary nerve** itself. - This block is used to anesthetize the sensory innervation of structures supplied by the nasociliary nerve, such as parts of the **nasal cavity**, **eyeball**, and **skin of the nose**. *Greater palatine nerve* - The **greater palatine nerve** supplies sensation to the posterior hard palate and is targeted in a **greater palatine nerve block**. - This nerve is a branch of the **maxillary nerve** and is primarily involved in dental and palatal anesthesia. *Sphenopalatine nerve* - The **sphenopalatine nerve**, or pterygopalatine ganglion, contains sensory fibers for the nasal cavity, palate, and pharynx, and its block is distinct from a nasociliary block. - A **sphenopalatine ganglion block** is mainly used for conditions like cluster headaches and facial pain, not for direct eyeball sensation. *Anterior ethmoidal nerve* - The **anterior ethmoidal nerve** is a branch of the nasociliary nerve, but a nasociliary nerve block targets the main trunk, which includes all its branches. - While the anterior ethmoidal nerve supplies the anterior part of the nasal septum and lateral wall, it is a **component** of the nasociliary innervation rather than the sole target.
Get full access to all questions, explanations, and performance tracking.
Start For Free